Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. (28th October 2016)

• Record Type: Journal Article
• Authors: Schoonjans, A.; Paelinck, B. P.; Marchau, F.; Gunning, B.; Gammaitoni, A.; Galer, B. S.; Lagae, L.; Ceulemans, B.
• Is Part Of: European journal of neurology. Volume 24:Number 2(2017:Feb.)
• Page Start: 309
• Page End: 314
• Publication Date: 2016-10-28
• Subjects: clinical trial -- Dravet syndrome -- epileptic encephalopathy -- orphan drug -- refractory epilepsy -- serotonin -- severe myoclonic epilepsy in infancy; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.13195
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: Dravet syndrome (DS) is a severe, drug‐resistant epilepsy. Fenfluramine has been reported to have a long‐term clinically meaningful anticonvulsive effect in patients with DS. Methods: This prospective, open‐label study assessed the safety and effectiveness of low‐dose fenfluramine in a new cohort of patients with DS. Following a 3‐month baseline period, fenfluramine was added to each patient's current antiepileptic drug regimen at a dose of 0.25–1.0 mg/kg/day (max. 20 mg/day). The incidence of major motor seizures (tonic, clonic, tonic–clonic, atonic and myoclonic seizures lasting >30 s) in both the baseline and treatment periods was assessed via a seizure diary. Periodic echocardiographic examinations during the treatment period were used to assess cardiovascular safety. Results: Nine patients (aged 1.2–29.8 years) enrolled in the study and were treated with fenfluramine for a median duration of 1.5 (range, 0.3–5.1) years. Median frequency of major motor seizures was 15.0/month in the baseline period. All patients demonstrated a reduction in seizure frequency during the treatment period with a median reduction of 75% (range, 28–100%). Seven patients (78%) experienced a ≥50% reduction in major motor seizure frequency. The most common adverse events were somnolence ( n = 5) and anorexia ( n = 4). No evidence of cardiac valvulopathy or pulmonary hypertension was observed. Conclusions: The effectiveness and safety of low‐dose fenfluramine as an add‐on therapy for DS in this new prospective cohort supports previous findings.